Introduction: Cranial radiotherapy is an established treatment for intracranial germinoma but may lead to late cerebrovascular complications including radiation-induced vasculopathy, cavernoma formation, and premature intracranial atherosclerosis. These complications may manifest many years after treatment and represent an important cause of stroke in young adult survivors of brain tumors. Case: We report a 39-year-old male with a history of suprasellar germinoma treated with transsphenoidal surgery followed by craniospinal radiotherapy in 2006. He subsequently developed panhypopituitarism requiring lifelong hormone replacement therapy. In October 2024, he experienced a cerebrovascular accident resulting in mild residual right-sided weakness. Brain magnetic resonance imaging demonstrated multifocal old infarcts, small vessel disease (Fazekas grade 2), and multiple susceptibility artifacts suggestive of radiation-induced cavernomas.In March 2026, he presented with new onset right-sided weakness and facial asymmetry. Initial neurological examination revealed right-sided motor power of 4/5. Computed tomography of the brain showed no acute intracranial hemorrhage but confirmed multiple old infarcts and small vessel ischemic changes. Computed tomography angiography revealed intracranial atherosclerotic disease with 25–50% stenosis of the cavernous segments of both internal carotid arteries and mild irregularities of posterior circulation vessels without evidence of large vessel occlusion or aneurysm. Radiation-induced vasculopathy is a recognized delayed complication of cranial irradiation, often presenting 5–25 years after treatment. Pathophysiological mechanisms include endothelial injury, accelerated atherosclerosis, and progressive arterial stenosis. In rare cases, cranial irradiation may also lead to secondary Moyamoya syndrome, characterized by progressive stenosis of the intracranial internal carotid arteries with development of collateral vessels. Although this patient’s vascular imaging did not demonstrate the characteristic collateral network seen in Moyamoya syndrome, it remains an important differential diagnosis in young patients presenting with recurrent stroke after cranial irradiation. In this patient, young age, prior cranial irradiation, multifocal infarcts, and coexisting radiation-induced cavernomas strongly suggest radiationrelated cerebrovascular disease as a major contributor to recurrent stroke. Conclusion Long-term survivors of intracranial germinoma treated with cranial radiotherapy remain at risk of delayed cerebrovascular complications. Early recognition and aggressive secondary stroke prevention, along with continued neurological surveillance, are essential to reduce morbidity in this population.
Ischemic Stroke ; Germinoma

Introduction: Graves’ disease may lead to thyrotoxic cardiomyopathy, a potentially reversible condition following restoration of euthyroidism. Radioiodine (RAI) therapy is commonly used as definitive treatment for patients with long-standing Graves’ disease or poor compliance with antithyroid medications. However, individuals with severe underlying cardiomyopathy may remain vulnerable to cardiovascular instability during the peri-treatment period. Case: We report a 39-year-old male with a 10-year history of Graves’ disease who had previously defaulted on follow-up and was admitted with thyroid storm. Echocardiography during that admission demonstrated severe dilated cardiomyopathy with global hypokinesia and an ejection fraction (EF) of 26%. Following treatment with carbimazole and propranolol, he achieved biochemical euthyroidism and remained clinically stable (NYHA class I). In view of his long-standing disease and prior thyroid storm, he underwent RAI therapy as definitive therapy as per the guidelines. One week following RAI, he developed a persistent cough and progressive dyspnea. Six weeks later, he presented to the emergency department with hypotension (BP 60/31 mmHg) and new-onset atrial fibrillation (heart rate 100 bpm), requiring intubation and inotropic support for cardiogenic shock. Laboratory evaluation showed low free T4 (5.31 pmol/L) with normal thyroid-stimulating hormone (2.1 mIU/L). Repeat echocardiography demonstrated persistent severe left ventricular dysfunction (EF ~25%) without new structural abnormalities. The patient improved rapidly with supportive management and was successfully extubated after stabilization. Although RAI is considered a safe and effective definitive therapy, transient thyroid hormone fluctuations and inflammatory thyroid destruction may occur following treatment. In patients with severe pre-existing cardiomyopathy, these physiological changes may precipitate arrhythmias or acute cardiac decompensation. In this case, new-onset atrial fibrillation in the setting of markedly reduced myocardial reserve likely triggered cardiogenic shock despite biochemical euthyroidism. Conclusion This case highlights that patients with advanced Graves’ cardiomyopathy may remain at risk of acute cardiovascular deterioration following RAI therapy. Careful cardiovascular risk assessment, optimization of heart failure therapy, and close monitoring after definitive treatment should be considered in this high-risk population.